Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.
The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on various biomarkers.
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
Among the brands comprising Calibre are Alpha-Tec Systems, EdgeBio, Microlytic, Molecular Dimensions, and NexTal, which it acquired from Qiagen earlier this year.